# cBioPortal Data Quality Assessment

**Date**: January 27, 2025  
**Study**: `ov_tcga_pan_can_atlas_2018`  
**Status**: ‚úÖ **COMPREHENSIVE DATA AVAILABLE**

---

## ‚úÖ **DATA AVAILABILITY SUMMARY**

| Data Type | Status | Coverage | Notes |
|-----------|--------|----------|-------|
| **Mutations** | ‚úÖ Available | Expected: ~300-400 patients | Gene, protein change, chromosome, position |
| **PFS (Progression-Free Survival)** | ‚úÖ Available | PFS_MONTHS + PFS_STATUS | Key outcome for benchmarking |
| **OS (Overall Survival)** | ‚úÖ Available | OS_MONTHS + OS_STATUS | Key outcome for benchmarking |
| **DFS (Disease-Free Survival)** | ‚úÖ Available | DFS_MONTHS + DFS_STATUS | Additional outcome metric |
| **Treatments** | ‚úÖ Available | 1,799 records, 64 unique drugs | Includes PARP inhibitors, platinum |
| **Response Rate** | ‚ö†Ô∏è Indirect | Via PFS_STATUS | No explicit ORR field, but PFS_STATUS indicates progression |

---

## üìä **CLINICAL ATTRIBUTES INVENTORY**

### **Survival Outcomes (11 fields)** ‚úÖ

1. **OS_MONTHS** (NUMBER)
   - Overall Survival in months
   - **Status**: ‚úÖ Available and populated
   - **Use Case**: Primary outcome for OS prediction benchmarking

2. **OS_STATUS** (STRING)
   - Format: `0:LIVING` or `1:DECEASED`
   - **Status**: ‚úÖ Available and populated
   - **Use Case**: Censoring indicator for survival analysis

3. **PFS_MONTHS** (NUMBER)
   - Progression-Free Survival in months
   - **Status**: ‚úÖ Available and populated
   - **Use Case**: Primary outcome for PFS prediction benchmarking

4. **PFS_STATUS** (STRING)
   - Format: `0:CENSORED`, `1:PROGRESSION`
   - **Status**: ‚úÖ Available and populated
   - **Use Case**: 
     - Censoring indicator for PFS analysis
     - **Proxy for response**: `0:CENSORED` = no progression (good response), `1:PROGRESSION` = progression (poor response)

5. **DFS_MONTHS** (NUMBER)
   - Disease-Free Survival in months
   - **Status**: ‚úÖ Available and populated

6. **DFS_STATUS** (STRING)
   - Format: `0:DiseaseFree`, `1:Recurred/Progressed`
   - **Status**: ‚úÖ Available and populated

7. **DSS_MONTHS** (NUMBER)
   - Disease-Specific Survival in months
   - **Status**: ‚úÖ Available

8. **DSS_STATUS** (STRING)
   - Disease-Specific Survival status
   - **Status**: ‚úÖ Available

### **Biomarkers & Demographics (49 fields)** ‚úÖ

**Key Fields for Benchmarking:**
- **AGE**: Diagnosis age
- **AJCC_PATHOLOGIC_TUMOR_STAGE**: Stage (IIIC, IV, etc.)
- **GRADE**: Histologic grade
- **CANCER_TYPE**: Ovarian cancer
- **TMB_NONSYNONYMOUS**: Tumor mutational burden
- **MSI_SCORE_MANTIS**: MSI status
- **FRACTION_GENOME_ALTERED**: Genomic instability

**Note**: HRD status and BRCA status are **NOT** in clinical attributes, but can be **inferred from mutations** (BRCA1/BRCA2 mutations ‚Üí HRD+)

---

## üíä **TREATMENT DATA INVENTORY**

### **Treatment Data Structure**

**Columns Available:**
- `treatment`: Drug name (string)
- `count`: Number of records (int)
- `patientId`: Patient identifier
- `sampleId`: Sample identifier
- `studyId`: Study identifier

**‚ö†Ô∏è Limitations:**
- No explicit response field in treatment data
- No treatment line information (first-line, second-line, maintenance)
- No treatment dates (start/end)
- No treatment response (CR, PR, SD, PD)

**‚úÖ What We Can Use:**
- Treatment presence/absence (patient received drug X)
- Treatment combinations (multiple drugs per patient)
- **Response inference**: Use PFS_STATUS from clinical data as proxy for treatment response

### **Key Treatments Available**

| Treatment | Records | Patients (est.) | Use Case |
|-----------|---------|-----------------|----------|
| **Carboplatin** | 450 | ~450 | Platinum chemotherapy (primary treatment) |
| **Cisplatin** | 143 | ~143 | Platinum chemotherapy (alternative) |
| **Olaparib** | 1 | 1 | PARP inhibitor (rare in TCGA) |
| **Bevacizumab** | 53 | ~53 | Anti-angiogenic (VEGF inhibitor) |
| **Paclitaxel** | (check) | (check) | Taxane chemotherapy |
| **Doxorubicin** | 143 | ~143 | Anthracycline |

**Note**: Most patients have multiple treatments (2-5 treatments per patient is common)

---

## üéØ **BENCHMARKING CAPABILITIES**

### **‚úÖ What We CAN Benchmark**

1. **PFS Prediction** ‚úÖ
   - **Input**: Patient mutations ‚Üí Our system efficacy scores
   - **Ground Truth**: PFS_MONTHS (continuous) + PFS_STATUS (censoring)
   - **Metric**: Correlation between efficacy scores and PFS
   - **Method**: Cox regression, Kaplan-Meier survival analysis

2. **OS Prediction** ‚úÖ
   - **Input**: Patient mutations ‚Üí Our system efficacy scores
   - **Ground Truth**: OS_MONTHS (continuous) + OS_STATUS (censoring)
   - **Metric**: Correlation between efficacy scores and OS
   - **Method**: Cox regression, Kaplan-Meier survival analysis

3. **Response Prediction (Proxy)** ‚úÖ
   - **Input**: Patient mutations ‚Üí Our system efficacy scores
   - **Ground Truth**: PFS_STATUS (`0:CENSORED` = good response, `1:PROGRESSION` = poor response)
   - **Metric**: Binary classification (response vs. progression)
   - **Method**: ROC-AUC, sensitivity, specificity

4. **Drug Ranking Accuracy** ‚ö†Ô∏è (Limited)
   - **Input**: Patient mutations ‚Üí Our system drug rankings
   - **Ground Truth**: Treatment data (which drugs patient received)
   - **Limitation**: No explicit "best drug" label, only treatment history
   - **Method**: Check if our top-ranked drugs match treatments patient received

5. **Platinum Response Prediction** ‚úÖ
   - **Input**: Patient mutations ‚Üí Our system efficacy scores for platinum
   - **Ground Truth**: PFS_STATUS for patients who received Carboplatin/Cisplatin
   - **Metric**: Binary classification (sensitive vs. resistant)
   - **Method**: ROC-AUC, sensitivity, specificity

### **‚ùå What We CANNOT Benchmark**

1. **Explicit Response Rates (ORR)** ‚ùå
   - No ORR (Objective Response Rate) field
   - No CR/PR/SD/PD (Complete Response, Partial Response, Stable Disease, Progressive Disease) fields
   - **Workaround**: Use PFS_STATUS as proxy

2. **Treatment Line Stratification** ‚ùå
   - No first-line vs. second-line vs. maintenance information
   - Cannot stratify by treatment line

3. **Treatment Response per Drug** ‚ùå
   - No explicit response field for each treatment
   - Cannot say "patient responded to olaparib but not to carboplatin"

4. **PARP Inhibitor Response** ‚ö†Ô∏è (Very Limited)
   - Only 1 patient with Olaparib in dataset
   - Insufficient sample size for PARP-specific benchmarking

---

## üìã **DATA EXTRACTION REQUIREMENTS**

### **Required Fields for Benchmarking**

#### **Mutations** (Required)
- `gene`: Gene symbol (e.g., BRCA1, TP53)
- `protein_change`: HGVS protein notation (e.g., p.Arg175His)
- `chromosome`: Chromosome number
- `position`: Genomic position
- `ref`: Reference allele
- `alt`: Alternate allele

#### **Clinical Outcomes** (Required)
- `OS_MONTHS`: Overall survival in months
- `OS_STATUS`: Overall survival status (0:LIVING, 1:DECEASED)
- `PFS_MONTHS`: Progression-free survival in months
- `PFS_STATUS`: Progression-free survival status (0:CENSORED, 1:PROGRESSION)

#### **Clinical Outcomes** (Optional but Valuable)
- `DFS_MONTHS`: Disease-free survival in months
- `DFS_STATUS`: Disease-free survival status
- `AGE`: Patient age
- `AJCC_PATHOLOGIC_TUMOR_STAGE`: Tumor stage
- `GRADE`: Histologic grade
- `TMB_NONSYNONYMOUS`: Tumor mutational burden

#### **Treatments** (Required for Drug Ranking)
- `treatment`: Drug name
- `patientId`: Patient identifier (to link with mutations/outcomes)

---

## üîç **DATA QUALITY VALIDATION CHECKLIST**

### **Pre-Extraction Validation**

- [x] ‚úÖ Mutations profile exists (`ov_tcga_pan_can_atlas_2018_mutations`)
- [x] ‚úÖ Sample list exists (`ov_tcga_pan_can_atlas_2018_all`)
- [x] ‚úÖ Clinical attributes available (60 attributes)
- [x] ‚úÖ Treatment data available (1,799 records)
- [x] ‚úÖ PFS_MONTHS and PFS_STATUS available
- [x] ‚úÖ OS_MONTHS and OS_STATUS available

### **Post-Extraction Validation**

- [ ] **Mutations Coverage**: ‚â•80% of patients have ‚â•1 mutation
- [ ] **Outcome Coverage**: ‚â•80% of patients have PFS_MONTHS and OS_MONTHS
- [ ] **Treatment Coverage**: ‚â•50% of patients have treatment data
- [ ] **Data Completeness**: ‚â•70% of patients have mutations + outcomes + treatments
- [ ] **Data Quality**: 
  - No duplicate patient IDs
  - PFS_MONTHS ‚â• 0 for all patients
  - OS_MONTHS ‚â• 0 for all patients
  - PFS_STATUS values are valid (`0:CENSORED`, `1:PROGRESSION`)
  - OS_STATUS values are valid (`0:LIVING`, `1:DECEASED`)

### **Benchmarking Readiness Validation**

- [ ] **Sample Size**: ‚â•200 patients with complete data (mutations + outcomes)
- [ ] **Event Rate**: ‚â•30% of patients have events (progression or death)
- [ ] **Treatment Diversity**: ‚â•10 unique treatments represented
- [ ] **Platinum Coverage**: ‚â•100 patients received Carboplatin or Cisplatin

---

## üöÄ **NEXT STEPS**

1. **‚úÖ Complete**: Data availability assessment
2. **‚è≥ In Progress**: Update extraction script with all validated fields
3. **‚è∏Ô∏è Pending**: Run extraction script on `ov_tcga_pan_can_atlas_2018`
4. **‚è∏Ô∏è Pending**: Validate extracted dataset against quality checklist
5. **‚è∏Ô∏è Pending**: Create benchmark script using extracted data

---

## üìä **EXPECTED DATASET STATISTICS**

Based on cBioPortal metadata:

- **Total Patients**: ~300-400 (exact count from extraction)
- **Patients with Mutations**: ~250-350 (80-90% coverage expected)
- **Patients with PFS Data**: ~250-350 (80-90% coverage expected)
- **Patients with OS Data**: ~250-350 (80-90% coverage expected)
- **Patients with Treatments**: ~200-300 (60-80% coverage expected)
- **Patients with Complete Data**: ~150-250 (50-70% coverage expected)

**Minimum Viable Dataset**: ‚â•200 patients with mutations + PFS + OS for benchmarking

---

**Status**: ‚úÖ **READY FOR EXTRACTION** - All required data fields are available and validated

